Secor Capital Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Secor Capital Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-16,215	Closed	-$151K	–	626
2018 Q4	$151K	Buy	+16,215	New	+$193K	0.02%	432
2018 Q2	–	Sell	-23,236	Closed	-$399K	–	678
2018 Q1	$399K	Buy	+23,236	New	+$453K	0.03%	398
2017 Q1	–	Sell	-23,893	Closed	-$1.2M	–	639
2016 Q4	$1.2M	Buy	23,893 +11,901	+99%	+$625K	0.15%	204
2016 Q3	$629K	Buy	+11,992	New	+$573K	0.07%	323
2015 Q3	–	Sell	-8,662	Closed	-$215K	–	651
2015 Q2	$215K	Sell	8,662 -1,058	-11%	-$23.6K	0.08%	364
2015 Q1	$222K	Buy	+9,720	New	+$245K	0.09%	376

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Secor Capital Advisors's FPRX Position: Q1 2019 in Review

Secor Capital Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2019, closing a stake of 16,215 shares — an estimated $151K sold.

Secor Capital Advisors first reported a position in FPRX in Q1 2015 and held it in 6 quarters. The position peaked at $1.2M in Q4 2016. 113 funds tracked by Wall St. Rank hold FPRX as of Q1 2019.

Secor Capital Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 16,215 Five Prime Therapeutics, Inc. shares in Q1 2019, an estimated $151K.
Secor Capital Advisors first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
Secor Capital Advisors's Five Prime Therapeutics, Inc. position peaked at $1.2M in Q4 2016.
113 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.